StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Prakash Gaba

BUYZydus Lifesciences Limited

byPrakash GabaHorizon: NA (inferred Intraday)26 Aug 2026, 8:49 am ISTvia CNBC Awaaz.

Entry₹1,127.4Inferred
Target₹1,150
Total upside +2.00% (call closed)
Stop loss₹1,120-0.66% risk
Exit₹1,12026 Aug 2026, 9:16 am
Stop-loss hit-0.66%
Follow Prakash Gaba for new calls(20% target hit, 256 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 26 Aug 2026
4 supporting0 opposing
Supports the BUY call (4)

1 other SEBI-registered advisor has an active intraday BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·25 Aug · today

Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection

NewsNdtv-Profit·21 Aug · 4d ago

(opens in new tab)

Zydus Lifesciences gets USFDA approval for generic Ascorbic Acid Injection

NewsCnbc-Tv18·21 Aug · 4d ago

(opens in new tab)

Zydus Lifesciences Ltd received final approval from the USFDA for Ascorbic Acid Injection, including 180-days CGT exclusivity.

BSE · Company Update·21 Aug · 4d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.